About Paul-Ehrlich-Institut
The Paul-Ehrlich-Institut is an institution of the Federal Republic of Germany. It is part of the portfolio of the Federal Ministry of Health. Various tasks laid down in German and European pharmaceutical legislation occupy the broadest area of its activities. Examples include the approval of clinical trials and the authorization of certain groups of medicinal products. Since its foundation more than a hundred years ago, the Paul-Ehrlich-Institut has concentrated on biomedical medicinal products: vaccines for humans and animals, antibody-containing medicinal products, allergens for therapy and diagnostics, blood and blood products and, more recently, tissues and medicinal products for gene therapy, somatic cell therapy and xenogeneic cell therapy, i.e. for procedures for research-related biomedical treatment. The approval and authorization-related activities, as well as the recording and evaluation of adverse effects (pharmacovigilance), aim to make medicinal products with a positive risk-benefit ratio available to the population. A significant contribution to the safety of biomedical medicinal products is made by the governmental experimental batch testing at the Paul-Ehrlich-Institut, which is independent of the manufacturer.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Pharma
